

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.org) on Apr 2, 2025

U-87MG ATCC

RRID:CVCL_0022

Type: Cell Line

Proper Citation

(RRID:CVCL_0022)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0022

Proper Citation: (RRID:CVCL_0022)

Sex: Male

Defining Citation: [PMID:327080](#), [PMID:450131](#), [PMID:833871](#), [PMID:3518877](#), [PMID:7459858](#), [PMID:7763724](#), [PMID:8069455](#), [PMID:9090379](#), [PMID:9230885](#), [PMID:9842975](#), [PMID:10074188](#), [PMID:10402232](#), [PMID:10416987](#), [PMID:10560660](#), [PMID:11414198](#), [PMID:11416159](#), [PMID:11966317](#), [PMID:14614447](#), [PMID:14655754](#), [PMID:14961077](#), [PMID:16232199](#), [PMID:16697959](#), [PMID:17595512](#), [PMID:19365568](#), [PMID:19435942](#), [PMID:20126413](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20587068](#), [PMID:20593219](#), [PMID:21406405](#), [PMID:22282976](#), [PMID:22460905](#), [PMID:22570425](#), [PMID:23325432](#), [PMID:25877200](#), [PMID:25894527](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:26496030](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:27412690](#), [PMID:27582061](#), [PMID:27894925](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:33385022](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: HLA class I peptidome analysis by proteomics., Omics: Genome sequenced., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: Deep antibody staining analysis., Omics: CRISPR phenotypic screen., Omics: CNV analysis., Omics: Cell surface proteome., Population: Caucasian., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misidentified. This cell line is not the original glioblastoma cell line established in 1968 at the University of Uppsala. As described in PubMed=27582061 it is most probably also a glioblastoma cell line but whose origin is

unknow. See U-87MG Uppsala (Cellosaurus=CVCL_GP63) for the original U-87MG cell line..

Category: Cancer cell line

Name: U-87MG ATCC

Synonyms: U-87MG, U-87 MG, U87 MG, U-87-MG, U87-MG, U87MG, U-87, U87, 87 MG, 87MG

Cross References: BTO:BTO_0002036, CLO:CLO_0009463, CLO:CLO_0009464, EFO:EFO_0005237, MCCL:MCC:0000469, CLDB:cl4592, CLDB:cl4594, CLDB:cl4595, CLDB:cl7166, Abcam:ab278079, AddexBio:C0005002/71, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-14, BCRC:60360, BCRJ:0241, BEI_Resources:ARP-2188, BioGRID_ORCS_Cell_line:348, BioSample:SAMN03472715, BioSample:SAMN03473126, BioSample:SAMN05292456, BioSample:SAMN07710026, BioSample:SAMN07710027, BioSample:SAMN07710028, BioSample:SAMN07710029, BioSample:SAMN07710030, BioSample:SAMN07710031, BioSample:SAMN07710032, BioSample:SAMN10988360, cancercellines:CVCL_0022, CCRID:1101HUM-PUMC000208, CCRID:3101HUMTCHu138, CCTCC:GDC0157, Cell_Model_Passport:SIDM01189, CGH-DB:157-1, ChEMBL-Cells:ChEMBL3307575, ChEMBL-Cells:ChEMBL3989361, ChEMBL-Targets:ChEMBL614247, CLS:300367, Cosmic:687590, Cosmic:849853, Cosmic:850741, Cosmic:850822, Cosmic:920816, Cosmic:1036336, Cosmic:1064099, Cosmic:1066234, Cosmic:1171224, Cosmic:1175825, Cosmic:1198263, Cosmic:1217671, Cosmic:1219449, Cosmic:1237542, Cosmic:1294951, Cosmic:1610737, Cosmic:1746951, Cosmic:1945859, Cosmic:2302316, Cosmic:2367555, Cosmic:2491106, Cosmic:2516044, Cosmic:2550364, Cosmic:2568870, Cosmic:2580918, Cosmic:2701083, Cosmic-CLP:687590, DepMap:ACH-000075, ECACC:89081402, EGA:EGAS00001000978, ENCODE:ENCBS424ENC, GDSC:687590, GEO:GSM101687, GEO:GSM101688, GEO:GSM101676, GEO:GSM101686, GEO:GSM326243, GEO:GSM481417, GEO:GSM500897, GEO:GSM887723, GEO:GSM888817, GEO:GSM923437, GEO:GSM1374974, GEO:GSM1638668, GEO:GSM1670559, GEO:GSM2113436, GEO:GSM2113437, GEO:GSM2113438, GEO:GSM2113439, IARC_TP53:21096, IBRC:C10982, ICLC:HTL00013, IZSLER:BS TCL 189, KCB:KCB 2011101YJ, KCLB:30014, LiGeA:CCL_552, LINCS_HMS:50868, LINCS_LDP:LCL-1364, Lonza:37, Lonza:808, NCBI_Iran:C531, PharmacoDB:U87MG_1623_2019, PRIDE:PXD000589, PRIDE:PXD000661, PRIDE:PXD001565, PRIDE:PXD003790, Progenetix:CVCL_0022, PubChem_Cell_line:CVCL_0022, RCB:RCB0419, TOKU-E:3381, Ubigene:YC-C028, Wikidata:Q7863603

ID: CVCL_0022

Record Creation Time: 20250131T202832+0000

Record Last Update: 20250131T204825+0000

Ratings and Alerts

No rating or validation information has been found for U-87MG ATCC.

Warning: Problematic cell line: Misidentified. This cell line is not the original glioblastoma cell line established in 1968 at the University of Uppsala. As described in PubMed=27582061 it is most probably also a glioblastoma cell line but whose origin is unknow. See U-87MG Uppsala (CVCL_GP63) for the original U-87MG cell line.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00535.

Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: HLA class I peptidome analysis by proteomics., Omics: Genome sequenced., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: Deep antibody staining analysis., Omics: CRISPR phenotypic screen., Omics: CNV analysis., Omics: Cell surface proteome., Population: Caucasian., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misidentified. This cell line is not the original glioblastoma cell line established in 1968 at the University of Uppsala. As described in PubMed=27582061 it is most probably also a glioblastoma cell line but whose origin is unknow. See U-87MG Uppsala (Cellosaurus=CVCL_GP63) for the original U-87MG cell line.. **Warning:** Discontinued: RCB; RCB0419

Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: HLA class I peptidome analysis by proteomics., Omics: Genome sequenced., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: Deep antibody staining analysis., Omics: CRISPR phenotypic screen., Omics: CNV analysis., Omics: Cell surface proteome., Population: Caucasian., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misidentified. This cell line is not the original glioblastoma cell line established in 1968 at the University of Uppsala. As described in PubMed=27582061 it is most probably also a glioblastoma cell line but whose origin is unknow. See U-87MG Uppsala (Cellosaurus=CVCL_GP63) for the original U-87MG cell line..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3341 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Villani S, et al. (2024) Selective inhibition of indoleamine and tryptophan 2,3-dioxygenases: Comparative study on kynurenine pathway in cell lines via LC-MS/MS-based targeted metabolomics. *Journal of pharmaceutical and biomedical analysis*, 237, 115750.

Sovilj D, et al. (2024) Cell-specific modulation of mitochondrial respiration and metabolism by the pro-apoptotic Bcl-2 family members Bax and Bak. *Apoptosis : an international journal on programmed cell death*, 29(3-4), 424.

Kawaai K, et al. (2024) Chordoma cells possess bone-dissolving activity at the bone invasion front. *Cellular oncology (Dordrecht, Netherlands)*, 47(5), 1663.

Lee SY, et al. (2024) Migrasomal autophagosomes relieve endoplasmic reticulum stress in glioblastoma cells. *BMC biology*, 22(1), 23.

Takaki EO, et al. (2024) A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(16), 3603.

Prado MB, et al. (2024) Prion protein regulates invasiveness in glioblastoma stem cells. *BMC cancer*, 24(1), 1539.

Barone TA, et al. (2024) FACT inhibitor CBL0137, administered in an optimized schedule, potentiates radiation therapy for glioblastoma by suppressing DNA damage repair. *Research square*.

Nguyen KT, et al. (2024) ProDiVis: a method to normalize fluorescence signal localization in 3D specimens. *Frontiers in cell and developmental biology*, 12, 1420161.

Zhu R, et al. (2024) ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion. *Cell metabolism*.

Habashy KJ, et al. (2024) Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(8), 1619.

Kandpal M, et al. (2024) Gut-brain axis interplay via STAT3 pathway: Implications of *Helicobacter pylori* derived secretome on inflammation and Alzheimer's disease. *Virulence*, 15(1), 2303853.

Li Y, et al. (2024) Mechanisms of Glioblastoma Replication: Ca²⁺ Flares and Cl⁻ Currents. *Molecular cancer research : MCR*, 22(9), 852.

Ramar V, et al. (2024) Interaction of NF- κ B and FOSL1 drives glioma stemness. *Cellular and molecular life sciences : CMLS*, 81(1), 255.

Tsung K, et al. (2024) CRISPRi screen of long non-coding RNAs identifies LINC03045 regulating glioblastoma invasion. *PLoS genetics*, 20(6), e1011314.

Lee YB, et al. (2024) Function of a complex of p-Y42 RhoA GTPase and pyruvate kinase M2 in EGF signaling pathway in glioma cells. *Journal of neurochemistry*.

Barone TA, et al. (2024) FACT inhibitor CBL0137, administered in an optimized schedule, potentiates radiation therapy for glioblastoma by suppressing DNA damage repair. *Journal of neuro-oncology*.

Zhao K, et al. (2024) Nerve Growth Factor Signaling Promotes Nuclear Translocation of TRAF4 to Enhance Tumor Stemness and Metastatic Dormancy Via C-Jun-mediated IL-8 Autocrine. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e2414437.

Ao H, et al. (2024) Enhanced anti-glioma activity of annonaceous acetogenins based on a novel liposomal co-delivery system with ginsenoside Rh2. *Drug delivery*, 31(1), 2324716.

O'Connor JPB, et al. (2024) Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action. *Cancer research communications*, 4(10), 2565.

Ohta K, et al. (2024) Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer. *Cancer research communications*, 4(9), 2514.